Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

• Status: Active, not recruiting
• Trial end date: 2021-02-13
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nevada, Reno
• Collaborator: Renown Regional Medical Center
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Vancomycin

Criteria

Inclusion Criteria:

1. Age ≥18 years

2. Previous CDI diagnosis

3. Current admission with a suspected or a confirmed bacterial infection requiring antibiotics

Exclusion Criteria:

1. Active chronic diarrheal illness (eg, Crohn's disease, ulcerative colitis, short bowel syndrome)

2. Previous adverse reactions to oral vancomycin

3. Requiring metronidazole during hospitalization

4. Known pregnancy

5. Expected survival <72 hours

6. Patients receiving antibiotics only for surgical prophylaxis

7. Patients who received prophylactic oral vancomycin for the current antibiotic course prior to enrollment in the study